Literature DB >> 33574274

Elucidating the mechanisms by which disulfiram protects against obesity and metabolic syndrome.

Michel Bernier1, Dylan Harney2, Yen Chin Koay2,3, Antonio Diaz4, Abhishek Singh5, Devin Wahl1,2,6, Tamara Pulpitel2,6, Ahmed Ali1, Vince Guiterrez1, Sarah J Mitchell1, Eun-Young Kim1,7, John Mach8, Nathan L Price5, Miguel A Aon1, David G LeCouteur2,6, Victoria C Cogger2,6, Carlos Fernandez-Hernando5, John O'Sullivan2,3, Mark Larance2, Ana Maria Cuervo4, Rafael de Cabo9.   

Abstract

There is an unmet need and urgency to find safe and effective anti-obesity interventions. Our recent study in mice fed on obesogenic diet found that treatment with the alcohol aversive drug disulfiram reduced feeding efficiency and led to a decrease in body weight and an increase in energy expenditure. The intervention with disulfiram improved glucose tolerance and insulin sensitivity, and mitigated metabolic dysfunctions in various organs through poorly defined mechanisms. Here, integrated analysis of transcriptomic and proteomic data from mouse and rat livers unveiled comparable signatures in response to disulfiram, revealing pathways associated with lipid and energy metabolism, redox, and detoxification. In cell culture, disulfiram was found to be a potent activator of autophagy, the malfunctioning of which has negative consequences on metabolic regulation. Thus, repurposing disulfiram may represent a potent strategy to combat obesity.

Year:  2020        PMID: 33574274     DOI: 10.1038/s41514-020-0046-6

Source DB:  PubMed          Journal:  NPJ Aging Mech Dis        ISSN: 2056-3973


  54 in total

1.  Fast food and sedentary lifestyle: a combination that leads to obesity.

Authors:  David R Jacobs
Journal:  Am J Clin Nutr       Date:  2006-02       Impact factor: 7.045

2.  Treatment of obesity with celastrol.

Authors:  Junli Liu; Jaemin Lee; Mario Andres Salazar Hernandez; Ralph Mazitschek; Umut Ozcan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

Review 3.  Appetite control and energy balance: impact of exercise.

Authors:  J E Blundell; C Gibbons; P Caudwell; G Finlayson; M Hopkins
Journal:  Obes Rev       Date:  2015-02       Impact factor: 9.213

4.  Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.

Authors:  Carmelo Quarta; Christoffer Clemmensen; Zhimeng Zhu; Bin Yang; Sini S Joseph; Dominik Lutter; Chun-Xia Yi; Elisabeth Graf; Cristina García-Cáceres; Beata Legutko; Katrin Fischer; Robert Brommage; Philippe Zizzari; Bernardo S Franklin; Martin Krueger; Marco Koch; Sabine Vettorazzi; Pengyun Li; Susanna M Hofmann; Mostafa Bakhti; Aimée Bastidas-Ponce; Heiko Lickert; Tim M Strom; Valerie Gailus-Durner; Ingo Bechmann; Diego Perez-Tilve; Jan Tuckermann; Martin Hrabě de Angelis; Darleen Sandoval; Daniela Cota; Eicke Latz; Randy J Seeley; Timo D Müller; Richard D DiMarchi; Brian Finan; Matthias H Tschöp
Journal:  Cell Metab       Date:  2017-09-21       Impact factor: 27.287

5.  Pyrrolidine dithiocarbamate enhances hepatic glycogen synthesis and reduces FoxO1-mediated gene transcription in type 2 diabetic rats.

Authors:  Tienian Zhu; Ruijing Zhao; Lizhong Zhang; Michel Bernier; Jiankun Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-11-29       Impact factor: 4.310

Review 6.  Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.

Authors:  B Cvek
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 7.  Long-term drug treatment for obesity: a systematic and clinical review.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

Review 8.  Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

Authors:  Rohan Khera; Mohammad Hassan Murad; Apoorva K Chandar; Parambir S Dulai; Zhen Wang; Larry J Prokop; Rohit Loomba; Michael Camilleri; Siddharth Singh
Journal:  JAMA       Date:  2016-06-14       Impact factor: 56.272

9.  Leptin therapy, insulin sensitivity, and glucose homeostasis.

Authors:  Gilberto Paz-Filho; Claudio Mastronardi; Ma-Li Wong; Julio Licinio
Journal:  Indian J Endocrinol Metab       Date:  2012-12

10.  Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.

Authors:  R Schreck; B Meier; D N Männel; W Dröge; P A Baeuerle
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.